ClinicalTrials.gg

TargetBeta

GCGR

glucagon receptor · also GGR · Glucagon receptor family

7 programs in company-led studies act on GCGR, from 7 companies: 4 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
UBT251The United Laboratories Internationalphase 31212 runningGIPR, GLP1Ra judged reading
retatrutideruleEli Lillyphase 33311 runningGIPR, GLP1RChEMBL
survodutideBoehringer Ingelheimphase 33510 runningGLP1Rthe company's pipeline
DR10624ruleHuadong Medicinephase 364 runningGLP1Rthe studies' text
AZD9550AstraZenecaphase 275 runningGLP1Ra judged reading
HRS-4729Jiangsu HengRui Medicinephase 254 runningGIPR, GLP1Rthe company's pipeline
efinopegdutideJohnson & Johnsonphase 2150 runningGLP1Ra judged reading

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.